MarketCap
Facebook
X
TelegramCountry |
 Bermuda |
IPO year |
2014 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
2.91 M |
Market Cap[1] |
$ 39.2 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Axsome Therapeutics
AXSM
|
$ 143.88 | -0.8 % | $ 7.16 B | Nasdaq Global Market,SPB |  USA |
 |
Heat Biologics, Inc.
HTBX
|
- | -5.76 % | $ 99.8 M | Nasdaq Capital Market | USA |
 |
Kindred Biosciences, Inc.
KIN
|
- | 0.11 % | $ 419 M | Nasdaq Global Select Market | USA |
 |
BioNTech SE
BNTX
|
$ 86.9 | -1.38 % | $ 21 B | Nasdaq Global Select Market |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
$ 2.1 | 0.48 % | $ 13.4 B | Nasdaq Capital Market |  Australia |
 |
Shineco, Inc.
TYHT
|
- | -3.90 % | $ 97.2 M | Nasdaq Global Select Market |  China |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.41 | -7.24 % | $ 44 M | NYSE American | USA |
 |
Millendo Therapeutics, Inc.
MLND
|
- | -5.36 % | $ 20.2 M | Nasdaq Global Select Market | USA |
 |
Aytu BioScience
AYTU
|
$ 1.93 | 1.58 % | $ 23.8 M | Nasdaq Capital Market | USA |
 |
Codexis
CDXS
|
$ 1.29 | 0.39 % | $ 112 M | Nasdaq Global Select Market | USA |
 |
Intec Pharma Ltd
NTEC
|
- | -12.45 % | $ 17.7 M | Nasdaq Capital Market |  Israel |
 |
Genmab A/S
GMAB
|
$ 44.64 | 1.94 % | $ 2.89 B | Nasdaq Global Select Market |  Danmark |
 |
GeoVax Labs
GOVX
|
$ 0.19 | -7.18 % | $ 182 K | Nasdaq Global Select Market | USA |
 |
Cellectar Biosciences
CLRB
|
$ 1.23 | 0.82 % | $ 3.21 M | Nasdaq Capital Market | USA |
 |
Galectin Therapeutics
GALT
|
$ 3.19 | -0.31 % | $ 204 M | Nasdaq Global Select Market | USA |
 |
GT Biopharma
GTBP
|
$ 5.17 | -5.31 % | $ 28.5 M | Nasdaq Capital Market | USA |
 |
Progenity, Inc.
PROG
|
- | -3.47 % | $ 164 M | Nasdaq Global Select Market | USA |
 |
Genprex
GNPX
|
$ 1.81 | 0.22 % | $ 1.69 M | Nasdaq Capital Market | USA |
 |
Strongbridge Biopharma plc
SBBP
|
- | 1.52 % | $ 136 M | Nasdaq Global Select Market | USA |
 |
Cue Biopharma
CUE
|
$ 18.45 | -1.1 % | $ 1.75 B | Nasdaq Capital Market,SPB | USA |
 |
Seneca Biopharma, Inc.
SNCA
|
- | -1.19 % | $ 28.7 M | Nasdaq Capital Market | USA |
 |
DiaMedica Therapeutics
DMAC
|
$ 8.74 | 0.23 % | $ 411 M | Nasdaq Capital Market | USA |
 |
Cardiff Oncology
CRDF
|
$ 0.81 | -10.82 % | $ 54.1 M | Nasdaq Capital Market | USA |
 |
Inhibrx
INBX
|
$ 88.26 | -5.48 % | $ 4.16 B | Nasdaq Global Select Market | USA |
 |
Kazia Therapeutics Limited
KZIA
|
$ 7.91 | 1.28 % | $ 121 M | Nasdaq Global Select Market | Australia |
 |
Fate Therapeutics
FATE
|
$ 2.06 | -2.61 % | $ 245 M | Nasdaq Global Market,SPB | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 50.15 | 0.3 % | $ 1.35 B | Nasdaq Global Market | USA |
 |
Fulcrum Therapeutics
FULC
|
$ 3.65 | -0.95 % | $ 231 M | Nasdaq Global Market | USA |
 |
Hutchison China MediTech Limited
HCM
|
$ 14.31 | -0.38 % | $ 12.3 B | Nasdaq Global Select Market | China |
 |
IDEAYA Biosciences
IDYA
|
$ 33.2 | -4.35 % | $ 2.94 B | Nasdaq Global Select Market | USA |
 |
InflaRx N.V.
IFRX
|
$ 1.57 | 0.32 % | $ 106 M | Nasdaq Global Select Market | Germany |
 |
Immutep Limited
IMMP
|
$ 3.07 | -4.06 % | $ 4.47 B | Nasdaq Global Market | Australia |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.89 | -6.44 % | $ 1.27 B | Nasdaq Capital Market | Israel |
 |
Zoetis
ZTS
|
$ 80.89 | -0.17 % | $ 35.9 B | NYSE,SPB | USA |
 |
Kala Pharmaceuticals
KALA
|
$ 0.19 | -1.95 % | $ 1.55 M | Nasdaq Global Select Market | USA |
 |
Mereo BioPharma Group plc
MREO
|
$ 0.28 | -1.99 % | $ 223 M | Nasdaq Global Select Market |  Britain |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 73.0 | -4.87 % | $ 5.42 B | Nasdaq Global Select Market | USA |
 |
Karyopharm Therapeutics
KPTI
|
$ 0.48 | -6.34 % | $ 5.25 K | Nasdaq Global Select Market | USA |
 |
MediciNova
MNOV
|
$ 1.41 | 1.44 % | $ 69.2 M | Nasdaq Global Market | USA |
 |
Seres Therapeutics
MCRB
|
$ 2.01 | -3.83 % | $ 17.8 M | Nasdaq Global Select Market | USA |
 |
MediWound Ltd.
MDWD
|
$ 12.1 | 0.83 % | $ 329 M | Nasdaq Global Select Market | Israel |
 |
SELLAS Life Sciences Group
SLS
|
$ 11.35 | -1.69 % | $ 1.24 B | Nasdaq Capital Market | USA |
 |
Precigen
PGEN
|
$ 6.05 | -2.34 % | $ 1.89 B | Nasdaq Global Select Market | USA |
 |
PolyPid Ltd.
PYPD
|
$ 5.3 | 0.95 % | $ 86.7 M | Nasdaq Global Select Market | Israel |
 |
Rocket Pharmaceuticals
RCKT
|
$ 2.27 | -0.87 % | $ 252 M | Nasdaq Global Select Market | USA |
 |
Avidity Biosciences
RNA
|
$ 8.04 | -1.93 % | $ 1.11 B | Nasdaq Global Select Market | USA |
 |
Summit Therapeutics
SMMT
|
$ 14.5 | -6.3 % | $ 10.8 B | Nasdaq Global Select Market | Britain |
 |
Celsion Corporation
CLSN
|
- | -6.63 % | $ 13.9 M | Nasdaq Capital Market | USA |
 |
Генетико
GECO
|
- | - | - | MOEX |  Russia |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.